Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-07-01
2010-06-15
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S282000
Reexamination Certificate
active
07737118
ABSTRACT:
A method of producing analgesia in a mammal is provided by rotational (alternating) intrathecal administration to the mammal of a pharmaceutically effective dose of at least one opioid receptor agonist, such as a μ-, δ-, or κ-opioid receptor agonist for a first period of time, followed by intrathecal administration to the mammal of a pharmaceutically effective dose of at least one opioid receptor-like receptor 1 (ORL-1) agonist for a second period of time. The intrathecal drug administration of the first and second periods of time may be repeated a plurality of times without attaining tolerance in the mammal to either drug. Implantable apparatus for rotational administration of the active agents is also disclosed.
REFERENCES:
patent: 5512578 (1996-04-01), Crain et al.
patent: 5711316 (1998-01-01), Elsberry et al.
patent: 5713923 (1998-02-01), Ward et al.
patent: 5735814 (1998-04-01), Elsberry et al.
patent: 5752930 (1998-05-01), Rise et al.
patent: 5782798 (1998-07-01), Rise
patent: 5798114 (1998-08-01), Elsberry et al.
patent: 5814014 (1998-09-01), Elsberry et al.
patent: 5820589 (1998-10-01), Torgerson et al.
patent: 5821219 (1998-10-01), Grandy et al.
patent: 5832932 (1998-11-01), Elsberry et al.
patent: 5975085 (1999-11-01), Rise
patent: 5978702 (1999-11-01), Ward et al.
patent: 6071925 (2000-06-01), Adam et al.
patent: 6075034 (2000-06-01), Adam et al.
patent: 6113527 (2000-09-01), Adam et al.
patent: 6172067 (2001-01-01), Ito et al.
patent: 6262066 (2001-07-01), Tulshian et al.
patent: 6277384 (2001-08-01), Kaiko et al.
patent: 6340681 (2002-01-01), Ito
patent: 1 048 308 (2000-11-01), None
patent: WO 97/40872 (1997-11-01), None
patent: WO 99/56803 (1999-11-01), None
patent: WO 00/66204 (2000-11-01), None
patent: WO 01/07050 (2001-02-01), None
patent: WO 01/93852 (2001-12-01), None
US 6,172,075, 01/2001, Adam et al. (withdrawn)
Hassenbusch et al., Journal of Pain and Symptom Management, 27(6):540-563, Jun. 2004.
Grisel et al., NeuroReport, 7:2125-2129, 1996.
Aves, Kenneth E., “Parenteral Preparations,”Remington's Pharmaceutical Sciences, Fifteenth Ed., 1975.
Wang, Yong-Xiang, et al., “Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats,”Pain, 84;271-281 (2000).
Jenck et al., “A synthetic agonist at the orphanin FQ
ociceptin receptor ORL1: anxiolytic profile in the rat,”Proc. Natl. Acad. Sci. U.S.A.97:4938-4943 (2000).
Jhamandas et al., “Antinociceptive and morphine modulatory actions of spinal orphanin FQ,”Can. J. Physiol Pharmacol. 76:314-324 (1998).
Dautzenberg et al., “Pharmacological characterization of the novel nonpeptide orphanin FQ
ociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo,”J. Pharmacol. Exp. Ther. 298:812-819 (2001).
Hao et al., “Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat,”Neurosci. Lett. 223:49-52 (1997).
Gouarderes et al., “Nociceptin receptors in the rat spinal cord during morphine tolerance,”Brain Res. 838:85-94 (1999).
Xu et al., “Effects of intrathecal orphanin FQ on a flexor reflex in the rat after inflammation or peripheral nerve section,”Eur.J.Pharmacol. 370:17-22 (1999).
Tian et al., “Endogenous orphanin FQ: evidence for a role in the modulation of electroacupuncture analgesia and the development of tolerance to analgesia produced by morphine and electroacupuncture,”Br. J. Pharmacol. 124:21-26 (1998).
Ueda et al., “Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence,”J. Neurosci. 20:7640-7647 (2000).
Mogil et al., “The molecular and behavioral pharmacology of the orphanin FQ
ociceptin peptide and receptor family,”Pharmacol.Rev. 53:381-415 (2001).
DeHaven-Hudkins et al., “Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity,”J. Pharmacol. Exp. Ther. 289:494-502 (1999).
Rizzi et al., “Effects of Ro 64/6198 in nociceptin/orphanin FQ-sensitive isolated tissues,”Naunyn Schmiedebergs Arch. Pharmacol. 363:551-555 (2001).
Higgins et al., “Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function,”Neuropharmacology41:97-107 (2001).
Ogawa et al., “Synthesis and in vivo evaluation of [11C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent,”Nucl. Med. Biol. 28:941-947 (2001).
Calo' et al., “Pharmacological profile of nociceptin/orphanin FQ receptors,”Clin. Exp. Pharmacol. Physiol29:223-228 (2002).
Calo' et al., “The orphan receptor and nociception 9 RC 2,”Euroanesthesia(2000).
Rover et al., “High-affinity, non-peptide agonists for the ORL1 (orphanin fq
ociceptin) receptor,”J. Med. Chem. 43:1329-1338 (2000).
Shimada et al., “Effects of flurbiprofen on extracapsular cataract extraction,”Journal of the Eye4:719-722 (1987), English abstract.
Medtronic Inc., “About Advanced Pain Therapies (APT),”Advanced Pain Therapies(2002).
Chung et al., “The efficacy of intrathecal neostigmine, intrathecal morphine, and their combination for post-cesarean section analgesia,”Anesth.Analg. 87:341-346 (1998) (Abstract only).
Yanez et al., “Intrathecal administration of morphine, midazolam, and their combination in 4 patients with chronic pain,”Rev. Esp. Anestesiol. Reanim. 39:40-42 (1992) (Abstract only).
Corradini et al., “The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats,”Brain Res. 905:127-133 (2001) (Abstract only).
Mogil et al., “Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ,”Neurosci. Lett. 214:131-134 (1996) (Abstract only).
Tian et al., “Functional studies using antibodies against orphanin FQ
ociceptin,”Peptides21:147-150 (2000) (Abstract only).
Yamamoto et al., “Inhibitory effect of intrathecally administered nociceptin on the expression of Fos-like immunoreactivity in the rat formalin test,”Neurosci. Lett. 284:155-158 (2000) (Abstract only).
Sakurada et al., “Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors,”Br. J. Pharmacol. 127:1712-1718 (1999) (Abstract only).
Grisel et al., “Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide,”Neuroreport7:2125-2129 (1996) (Abstract only).
Tian et al., “Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat,”Br. J. Pharmacol. 120:676-680 (1997) (Abstract only).
Yamamoto et al., “Nociceptin/orphanin FQ: role in nociceptive information processing,”Prog. Neurobiol. 57:527-535 (1999) (Abstract only).
Okuda et al., “Pharmacological profiles of J-113397, a novel nociceptin (orphanin FQ) antagonist in pain regulation,”Society for Neuroscience Abstracts26 (2000) (Abstract only).
Sutters et al., “Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids,”Brain Res. 530:290-294 (1990).
Miaskowski et al., “Kappa- and delta-opioid agonists synergize to produce potent analgesia,”Brain Res. 509:165-168 (1990).
Inoue et al., “Pronociceptive effects of nociceptin/orphanin FQ (13-17) at peripheral and spinal level in mice,”J. Pharmacol. Exp. Ther. 299:213-219 (2001) (Abstract only).
Smith et al., “Lack of cross-tolerance between intrathecal AM336 and intravenous morphine incontrast to the marked cross-tolerance between ziconotide and morphine,”Australian Society of Clinical and Experimental Pharmacologists and Toxicologi(2000) (Abstract only).
Stoelting, R. K., “Intrat
Demopulos Gregory A.
Palmer Pamela Pierce
Allen Marianne P
Kelbon Marcia S.
Omeros Corporation
Regents of the University of California
LandOfFree
Rotational intrathecal analgesia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rotational intrathecal analgesia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rotational intrathecal analgesia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181040